Apellis Pharmaceuticals, Inc.
APLSNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for APLS. That does not mean none is planned.
Get an email about APLS's next catalysts
Track Apellis Pharmaceuticals (APLS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
APL-2
Paroxysmal Nocturnal Hemoglobinuria
PEGCETACOPLAN (APL-2)
Geographic Atrophy Secondary to Age-related Macular Degeneration
Soliris
Paroxysmal Nocturnal Hemoglobinuria
APL-2, Pegcetacoplan
Geographic Atrophy Secondary to Age-related Macular Degeneration
APL-9
COVID
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
APL-2 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
PEGCETACOPLAN (APL-2) | Phase 3 | Geographic Atrophy Secondary to Age-related Macular Degeneration | - | - |
Soliris | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
APL-2, Pegcetacoplan | Phase 3 | Geographic Atrophy Secondary to Age-related Macular Degeneration | - | - |
APL-9 | Phase 2 | COVID | - | - |
Paroxysmal Nocturnal Hemoglobinuria
2 drugs in this indication
Geographic Atrophy Secondary to Age-related Macular Degeneration
2 drugs in this indication
FSGS
1 drug in this indication
COVID
1 drug in this indication
C3G
1 drug in this indication
Complement 3 Glomerulopathy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Apellis Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Apellis Pharmaceuticals, Inc.'s (APLS) pipeline across Phase 3, Phase 2. Its lead program is APL-2 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Apellis Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Apellis Pharmaceuticals, Inc. (APLS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track APLS biotech catalysts?→
Add APLS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Apellis Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.